p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy

Cancer

Volumn 85, Issue 6, 1999, Pages 1293-1299

  Cheng, Liang ^a   Sebo, Thomas J ^b   Cheville, John C ^b   Pisansky, Thomas M ^b   Slezak, Jeff ^b   Bergstralh, Erik J ^b   Pacelli, Anna ^b   Neumann, Roxann M ^b   Zincke, Horst ^c   Bostwick, David G ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c DEPARTMENT OF UROLOGY   (United States)

Author keywords

Glutathione S transferase; Ki 67 antigen; Prostate; Protein p53; Radiotherapy; Recurrent cancer

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CORRELATION FUNCTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 0033559960     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1293::AID-CNCR11>3.0.CO;2-O     Document Type: Article

References (51)

1. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of independent origin of multiple tumors from prostate cancer patients. J Natl Cancer Inst 1998;90:233-7.
2. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia (PIN): comparison with matched foci of prostate cancer. Cancer 1998;83:1995-2002.
3. Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998;58:23-8.
4. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995;55:2959-62.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991;253:49-53.
6. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8.
7. Levine AJ, Momand J, Finlay CA. The p53 tumors suppressor gene. Nature 1991;351:453-6.
8. Harris CC. Structural and function of the p53 tumor suppressor gene: clue for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-5.
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
10. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-51.
11. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancer. Cancer Res 1993;53:3369-73.
12. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996;56:3814-22.
13. Mirchandani D, Zheng J, Miler GJ, Ghosh AK, Shibata DK, Cote RJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147:92-101.
14. Aprikian AG, Sarkis AS, Fair WR, Zhang Z, Fuks Z, Cordo-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-80.
15. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158:131-7.
16. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995;45:470-5.
17. Moul JW, Betterncourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, et al. Protein expression of p53, bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159-66.
18. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-65.
19. Bauer JJ, Sesterhen IA, Mostofi KF, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995;1: 1295-300.
20. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. p53 immunohistochemistry and genetic alterations are associated at high incidence with postirradiated locally persistent prostate carcinoma. J Urol 1996; 155:1685-92.
21. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactiviry. J Urol 1998;159:1437-43.
22. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, DeVere White RW. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 1998;51:346-51.
23. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
24. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma is activated by either DNA damage or cellular differentiation. Nat Med 1996;2:804-10.
25. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GM, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
26. Fan S, El-Deiry WA, Bae I, Freeman J, Jondle D, Bhatia K, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
27. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
28. Westphal CH, Schmaltz C, Rowan S, Elson A, Fisher DE, Leder P. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res 1997;57:1664-7.
29. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995;5:3726-31.
30. Isaacs JS, Chiao C, Merrick A, Selkirk JK, Barrett JC, Weissman BE. p53-dependent p21 induction following gamma-irradiation without concomitant p53 induction in a human peripheral neuroepithelioma cell line. Cancer Res 1997;57: 2986-92.
31. Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995;154:1103-9.
32. Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM, et al. Predictors of survival in prostate cancer patients treated with salvage radical prostatectomy after radiation therapy. Cancer 1998;83:2164-71.
33. Bostwick DG, Myers RP, Osterling JE. Staging of prostate cancer. Semin Surg Oncol 1994;10:20-72.
34. Bostwick DG. Staging prostate cancer, 1997: current methods and limitations. Eur Urol 1997;32(Suppl 3):2-14.
35. Bostwick DG. Neoplasms of the prostate. In: Bostwick DG, Eble JN, editors. Urologic surgical pathology. 1st edition. St. Louis, MO: Mosby, 1997:343-422.
36. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
37. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody procedures. J Histochem Cytochem 1981;29:577-80.
38. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998;82:2262-9.
39. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR. The national cancer data base report on race, age, and region variations in prostate cancer treatment. Cancer 1997;80: 1261-6.
40. Kuban DA, Schellhammer PF. Prognostic significance of post-irradiation prostate biopsies. Oncology 1993;7:29-38.
41. Babaian RJ, Kojima M, Saitoh M, Ayala AG. Detection of residual prostate cancer after external radiotherapy: role of prostate specific antigen and transrectal ultrasonography. Cancer 1995;75:2153-8.
42. Bostwick DG. Practical clinical application of predictive factors in prostate cancer, with emphasis on quantitative methods in tissue specimens. Anal Quant Histol Cytol. In press.
43. Crook J, Robertson S, Esche B. Proliferative cell nuclear antigen in postradiotherapy prostate biopsies. Int J Radiat Oncol Biol Phys 1994;30:303-8.
44. O'Sullivan DC, Barrett DM, Colby TV, Lieber MM, Cupps RE. Effect of external beam radiotherapy on prostatic carcinoma DNA content as measured by static image cytometry. Eur Urol 1992;21:235-9.
45. Siders DB, Lee F. Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum Pathol 1992;23:344-51.
46. Wheeler JA, Zagars GK, Ayala AG. Dedifferentiation of locally recurrent prostate cancer after radiation therapy: evidence of tumor progression. Cancer 1993;71:3783-7.
47. Crook IM, Bahadur YA, Robertson SJ, Perry GA, Esche BA. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997;79:81-9.
48. Toffoli G, Viel A, Tumiotti L, Giannini F, Volpe R, Quaia M, et al. Expression of glutathione S-transferase-π in human tumors. Eur J Cancer 1992;28A:1441-6.
49. Moskaluk CA, Duray PH, Cowan HK, Linehan M, Merino M. Immunohistochemical expression of π-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate. Cancer 1997;79:1595-9.
50. Cookson MS, Reuter VE, Linkov I, Fair WR. Glutathione S-transferase pi (GST-π) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol 1997;157:673-6.
51. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.